Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 51

1.

Associations between UGT1A1*6 or UGT1A1*6/*28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients.

Han FF, Guo CL, Yu D, Zhu J, Gong LL, Li GR, Lv YL, Liu H, An GY, Liu LH.

Cancer Chemother Pharmacol. 2014 Apr;73(4):779-88. doi: 10.1007/s00280-014-2405-0. Epub 2014 Feb 12.

PMID:
24519753
[PubMed - indexed for MEDLINE]
2.

UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians.

Cheng L, Li M, Hu J, Ren W, Xie L, Sun ZP, Liu BR, Xu GX, Dong XL, Qian XP.

Cancer Chemother Pharmacol. 2014 Mar;73(3):551-60. doi: 10.1007/s00280-014-2382-3. Epub 2014 Jan 22. Review.

PMID:
24448639
[PubMed - indexed for MEDLINE]
3.

Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.

Hirata K, Nagata N, Kato T, Okuyama Y, Andoh H, Takahashi K, Oba K, Sakamoto J, Hazama S, Mishima H.

Anticancer Res. 2014 Jan;34(1):195-201.

PMID:
24403462
[PubMed - indexed for MEDLINE]
4.

Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics.

Chen S, St Jean P, Borland J, Song I, Yeo AJ, Piscitelli S, Rubio JP.

Pharmacogenomics. 2014 Jan;15(1):9-16. doi: 10.2217/pgs.13.190.

PMID:
24329186
[PubMed - indexed for MEDLINE]
Free Article
5.

UGT1A1 gene mutation due to Crigler-Najjar syndrome in Iranian patients: identification of a novel mutation.

Mohammadi Asl J, Tabatabaiefar MA, Galehdari H, Riahi K, Masbi MH, Zargar Shoshtari Z, Rahim F.

Biomed Res Int. 2013;2013:342371. doi: 10.1155/2013/342371. Epub 2013 Oct 28.

PMID:
24286076
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients.

Filopanti M, Barbieri AM, Mantovani G, Corbetta S, Gasco V, Ragonese M, Martini C, Bogazzi F, Colao A, Ferone D, Peri A, Pigliaru F, Angeletti G, Arosio M, Beck-Peccoz P, Lania AG, Spada A.

Eur J Endocrinol. 2013 Dec 21;170(2):247-54. doi: 10.1530/EJE-13-0657. Print 2014 Feb.

PMID:
24217933
[PubMed - indexed for MEDLINE]
7.

Relationship between the expression of CES2, UGT1A1, and GUSB in colorectal cancer tissues and aberrant methylation.

Xie FW, Peng Y, Chen X, Chen X, Li J, Wang W, Yu Z, Ouyang X.

Neoplasma. 2014;61(1):99-109.

PMID:
24195516
[PubMed - indexed for MEDLINE]
8.

Early complication in sickle cell anemia children due to A(TA)nTAA polymorphism at the promoter of UGT1A1 gene.

Chaouch L, Talbi E, Moumni I, Ben Chaabene A, Kalai M, Chaouachi D, Mallouli F, Ghanem A, Abbes S.

Dis Markers. 2013;35(2):67-72. doi: 10.1155/2013/173474. Epub 2013 Jul 28.

PMID:
24167350
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine.

Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MM.

Invest New Drugs. 2013 Dec;31(6):1559-67. doi: 10.1007/s10637-013-0034-9. Epub 2013 Oct 10.

PMID:
24114122
[PubMed - indexed for MEDLINE]
10.

Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms.

Motzer RJ, Johnson T, Choueiri TK, Deen KC, Xue Z, Pandite LN, Carpenter C, Xu CF.

Ann Oncol. 2013 Nov;24(11):2927-8. doi: 10.1093/annonc/mdt394. Epub 2013 Oct 9. No abstract available.

PMID:
24107802
[PubMed - indexed for MEDLINE]
11.

Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients.

Hirasawa A, Zama T, Akahane T, Nomura H, Kataoka F, Saito K, Okubo K, Tominaga E, Makita K, Susumu N, Kosaki K, Tanigawara Y, Aoki D.

J Hum Genet. 2013 Dec;58(12):794-8. doi: 10.1038/jhg.2013.105. Epub 2013 Oct 3. Erratum in: J Hum Genet. 2013 Dec;58(12):825.

PMID:
24088669
[PubMed - indexed for MEDLINE]
12.

Role of a homozygous A(TA)₇TAA promoter polymorphism and an exon 1 heterozygous frameshift mutation UGT1A1 in Crigler-Najjar syndrome type II in a Thai neonate.

Nilyanimit P, Krasaelap A, Foonoi M, Chongsrisawat V, Poovorawan Y.

Genet Mol Res. 2013 Sep 4;12(3):3391-7. doi: 10.4238/2013.September.4.5.

PMID:
24065680
[PubMed - indexed for MEDLINE]
Free Article
13.

UGT1A1 promoter polymorphism associated with serum bilirubin level in Saudi patients with sickle cell disease.

Hamad Z, Aljedai A, Halwani R, AlSultan A.

Ann Saudi Med. 2013 Jul-Aug;33(4):372-6. doi: 10.5144/0256-4947.2013.372.

PMID:
24060717
[PubMed - indexed for MEDLINE]
14.

Lack of association between the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphism and the risk of benign prostatic hyperplasia in Caucasian men.

Karatzas A, Tzortzis V, Giannatou E, Gravas S, Zachos I, Oeconomou A, Melekos M, Tsezou A.

Mol Biol Rep. 2013 Dec;40(12):6665-9. doi: 10.1007/s11033-013-2781-2. Epub 2013 Sep 21.

PMID:
24057187
[PubMed - indexed for MEDLINE]
15.

UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.

Hazama S, Mishima H, Tsunedomi R, Okuyama Y, Kato T, Takahashi K, Nozawa H, Ando H, Kobayashi M, Takemoto H, Nagata N, Kanekiyo S, Inoue Y, Hamamoto Y, Fujita Y, Hinoda Y, Okayama N, Oba K, Sakamoto J, Oka M.

Cancer Sci. 2013 Dec;104(12):1662-9. doi: 10.1111/cas.12283. Epub 2013 Oct 27.

PMID:
24033692
[PubMed - indexed for MEDLINE]
16.

Analysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in Shanghai.

Cai X, Cao W, Ding H, Liu T, Zhou X, Wang M, Zhong M, Zhao Z, Xu Q, Wang L.

J Cancer Res Clin Oncol. 2013 Sep;139(9):1579-89. doi: 10.1007/s00432-013-1480-7. Epub 2013 Jul 28.

PMID:
23892411
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.

Xu JM, Wang Y, Ge FJ, Lin L, Liu ZY, Sharma MR.

World J Gastroenterol. 2013 Jun 28;19(24):3899-903. doi: 10.3748/wjg.v19.i24.3899.

PMID:
23840132
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

UGT1A1 (TA)n genotyping in sickle-cell disease: high resolution melting (HRM) curve analysis or direct sequencing, what is the best way?

Thomas V, Mazard B, Garcia C, Lacan P, Gagnieu MC, Joly P.

Clin Chim Acta. 2013 Sep 23;424:258-60. doi: 10.1016/j.cca.2013.06.023. Epub 2013 Jul 1.

PMID:
23827693
[PubMed - indexed for MEDLINE]
Free Article
19.

Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy.

Takatori E, Shoji T, Miura Y, Takeuchi S, Yoshizaki A, Sugiyama T.

J Obstet Gynaecol Res. 2013 Aug;39(8):1354-8. doi: 10.1111/jog.12062. Epub 2013 Jun 26.

PMID:
23800356
[PubMed - indexed for MEDLINE]
20.

Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients.

Gao J, Zhou J, Li Y, Peng Z, Li Y, Wang X, Shen L.

Med Oncol. 2013;30(3):630. doi: 10.1007/s12032-013-0630-8. Epub 2013 Jun 20.

PMID:
23783485
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk